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ABSTRACT Seasonal inﬂuenza virus epidemics represent a signiﬁcant public health
burden. Approximately 25% of all inﬂuenza virus infections are caused by type B vi-
ruses, and these infections can be severe, especially in children. Current inﬂuenza vi-
rus vaccines are an effective prophylaxis against infection but are impacted by rapid
antigenic drift, which can lead to mismatches between vaccine strains and circulat-
ing strains. Here, we describe a broadly protective vaccine candidate based on chi-
meric hemagglutinins, consisting of globular head domains from exotic inﬂuenza A
viruses and stalk domains from inﬂuenza B viruses. Sequential vaccination with these
constructs in mice leads to the induction of broadly reactive antibodies that bind to
the conserved stalk domain of inﬂuenza B virus hemagglutinin. Vaccinated mice are
protected from lethal challenge with diverse inﬂuenza B viruses. Results from serum
transfer experiments and antibody-dependent cell-mediated cytotoxicity (ADCC) as-
says indicate that this protection is antibody mediated and based on Fc effector
functions. The present data suggest that chimeric hemagglutinin-based vaccination
is a viable strategy to broadly protect against inﬂuenza B virus infection.
IMPORTANCE While current inﬂuenza virus vaccines are effective, they are affected
by mismatches between vaccine strains and circulating strains. Furthermore, the an-
tiviral drug oseltamivir is less effective for treating inﬂuenza B virus infections than
for treating inﬂuenza A virus infections. A vaccine that induces broad and long-
lasting protection against inﬂuenza B viruses is therefore urgently needed.
KEYWORDS hemagglutinin, inﬂuenza B virus, vaccine
Inﬂuenza B viruses cause signiﬁcant morbidity and mortality annually on a global scale(1–4). Approximately 20 to 30% of all inﬂuenza cases are caused by inﬂuenza B
viruses, but occasionally, they are the dominant inﬂuenza type in a season (5–8). While
inﬂuenza B viruses are considered to cause less severe infections than H3N2 viruses,
they rank above pandemic H1N1 infections in severity (4, 9, 10). Inﬂuenza B virus is
speciﬁcally problematic in children and infants, where it can cause excess mortality. A
prime example is the 2010-2011 epidemic, where inﬂuenza B viruses caused 25% of all
inﬂuenza cases but were responsible for 38% of all inﬂuenza-related pediatric deaths
(11), a trend that was seen worldwide (8, 12, 13). Furthermore, a recent study found that
the proportion of deaths in children hospitalized with inﬂuenza attributable to inﬂu-
enza B virus is 1.1%, compared to 0.4% for inﬂuenza A virus (14). Finally, oseltamivir
treatment seems to be less effective against inﬂuenza B viruses than against inﬂuenza
A viruses (15–17), and oseltamivir-resistant mutants emerge (18–20), sometimes with-
out a loss of ﬁtness (21, 22).
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Current inﬂuenza virus vaccines are an effective prophylactic countermeasure
against inﬂuenza B virus infections. However, due to the antigenic drift in the globular
head domain of viral hemagglutinin (HA), these vaccines have to be reformulated and
readministered annually (23). Vaccine strain selection is based on surveillance and
predictions, and the selected vaccine strains do not always match the circulating
strains. A mismatch between vaccine strains and circulating strains can lead to a sharp
drop in vaccine effectiveness (2, 3, 7). This is further complicated by the fact that two
antigenically distinct inﬂuenza B virus lineages, B/Victoria/2/87-like (Victoria-like) vi-
ruses and B/Yamagata/16/88-like (Yamagata-like) viruses, cocirculate in the human
population (2, 4, 24). The introduction of quadrivalent inﬂuenza virus vaccines (QIVs),
which contain vaccine strains of both lineages, alleviates this problem but does not
solve the issues of constant antigenic drift, mismatch within a lineage, and waning of
vaccine effectiveness within a season (2, 4, 25).
Here, we describe a vaccine approach that refocuses the antibody response toward
the conserved stalk domain of HA. In contrast to the immunodominant head domain
of HA, the stalk domain is usually not a primary target of the immune system (26, 27).
Antibody titers against this domain in humans are low, but previous studies have
shown that antibodies that target the stalk can be broadly protective (28). To induce
protective antistalk antibody titers, we are using a vaccination strategy based on
chimeric HAs (cHAs) (29, 30) that has already been successfully applied as a universal
vaccine strategy for group 1 (31–35) and group 2 (36, 37) HA-expressing inﬂuenza A
viruses. Here, we constructed cHAs with different head domains derived from exotic
inﬂuenza A virus HA subtypes and stalk domains from inﬂuenza B virus HAs. These
inﬂuenza A/B virus HA chimeras (cHA/B) were used in sequential vaccination regimens
in mice to induce protective titers of stalk-reactive antibodies. We show that these
vaccine constructs protect mice against lethal challenge with diverse inﬂuenza B viruses
and that protection is mediated by antibodies, likely via Fc effector functions.
RESULTS
Design and construction of cHA/B HAs. Chimeric HAs are combinations of glob-
ular head domains from an HA of one inﬂuenza virus subtype or strain and the stalk
domain from an HA of another subtype/strain. This design has been successfully
applied to inﬂuenza A virus HAs, where a disulﬁde bond between two conserved
cysteines (C52 and C277 [H3 numbering]) was used as a demarcation line between
head and stalk regions (Fig. 1A) (29, 30). C52 and C277 are present in all inﬂuenza A
virus HAs, and their presence makes it relatively easy to graft a head domain from one
inﬂuenza A virus HA onto the stalk domain of another HA. The sequential presentation
of cHAs with conserved stalk domains but very different head domains refocuses the
immune response from the immunodominant head domain to the subdominant stalk
domain (38). However, the diversity of inﬂuenza B virus head domains is low compared
to that of inﬂuenza A virus head domains (2). We therefore rationalized that the use of
diverse inﬂuenza A virus HA head domains in combination with inﬂuenza B virus stalk
domains would be a better choice than making cHAs between different inﬂuenza B
virus HA head and stalk domains. The obstacle with this approach is that the disulﬁde
bond formed between C52 and C277 at the head/stalk interface, which is conserved in
inﬂuenza A virus HAs, is not present in inﬂuenza B virus HAs. This makes the grafting
of inﬂuenza A virus head domains onto inﬂuenza B virus stalk domains more challeng-
ing. By comparing structures and sequences of inﬂuenza A and B virus HAs, we
identiﬁed a pair of alanines (A57 and A306 [B/Yamagata/16/88 numbering, starting with
methionine]) in inﬂuenza B virus HA in a position homologous to those of the cysteines
in inﬂuenza A virus HA (Fig. 1B). We therefore designed two construct series. The
cHA/Bcys series includes the cysteines from inﬂuenza A virus HA with the alanines from
inﬂuenza B virus HA removed (Fig. 1C). The cHA/Bala series maintains the alanines from
inﬂuenza B virus HA with the inﬂuenza A virus HA cysteines deleted (Fig. 1D). Inﬂuenza
A virus head domains from H5, H7, and H8 HA were used to construct the cH5/Bcys,
cH7/Bcys, and cH8/Bcys and the cH5/Bala, cH7/Bala, and cH8/Bala series of antigens. The
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constructs where then subcloned into mammalian expression vectors, and their ex-
pression after transfection into human embryonic kidney 293T (HEK 293T) cells was
conﬁrmed by using immunoﬂuorescence microscopy (Fig. 1E). The cH7/Bcys, cH8/Bcys,
cH7/Bala, and cH8/Bala constructs were also expressed in the baculovirus system to
create protein antigens for vaccination.
FIG 1 Design of chimeric HA/B constructs. (A) Monomer of the H5 HA structure (based on data reported
under Protein Data Bank [PDB] accession number 2FK0 [52]). The head domain is shown in purple, and
the stalk domain is shown in blue. The head domain is located between cysteines 52 and 277 (H3
numbering), which form a disulﬁde bond. The cysteines are indicated by yellow arrows and are
highlighted in yellow on the structure. (B) Monomer of an inﬂuenza B virus HA (based on data reported
under PDB accession number 4M44 [53]). In this case, the stalk domain is shown in light green, and the
head domain is shown in dark green. The head domain is located between alanines 57 and 306
(B/Yamagata/16/88 numbering, starting with methionine), which are in positions on the structure similar
to those of C52 and C277 on inﬂuenza A virus HAs. The alanines are indicated by orange arrows and are
highlighted in orange on the structure. (C and D) The two cHA/B constructs that were generated with
head domains from inﬂuenza A virus HA and stalk domains from inﬂuenza B virus. (C) The inﬂuenza A
virus HA cysteines (now in positions C57/C306, labeled in purple, since they are derived from inﬂuenza
A virus HA) were maintained as the demarcation line between the head (purple) and stalk (green), and
the original inﬂuenza B virus alanines were deleted. (D) Similar construct where the alanines (labeled in
green since they are derived from inﬂuenza B virus HA) were maintained and the cysteines were
removed. *, the transmembrane domain (TM) (brown) and cytoplasmic tail domain (CTD) (blue) are
derived from A/Puerto Rico/8/34 HA for all constructs for technical reasons. (E) Immunostaining of HEK
293T cells transfected with different cHA/B constructs, wild-type inﬂuenza B virus HA (WT B HA) (from
B/Yamagata/16/88), or the empty vector (pDZ). cH5/Bcys contains the head domain of H5 HA combined
with the stalk domain of B/Yamagata/16/88 HA, with “cys” indicating that the design shown in panel C
was used. cH7/Bcys and cH8/Bcys were constructed in the same way, but the head domains are derived
from H7 and H8, respectively. cH5/Bala, cH7/Bala, and cH8/Bala are based on the designs shown in panel
D. Cells were stained with polyclonal anti-B/Yamagata/16/88 serum.
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Sequential vaccination with cHA/B HAs protects from challenge with diverse
inﬂuenza B virus strains. Next, we tested the protective effect of sequential vaccina-
tion with the cHA/B constructs in the mouse model. Animals were intramuscularly (i.m.)
primed with a DNA vaccine expressing cH5/Bcys or cH5/Bala and then vaccinated at
3-week intervals with cH7/Bcys or cH7/Bala proteins, followed by cH8/Bcys or cH8/Bala
proteins, respectively (Fig. 2A). Protein antigens were delivered both intranasally (i.n.)
and i.m. with poly(I·C) as an adjuvant. Control groups included prime-only animals that
received irrelevant protein vaccinations [bovine serum albumin (BSA) with poly(I·C)]
and naive animals. In addition, we added “standard-of-care” (SOC) positive-control
groups that received two i.m. doses (1 g of inﬂuenza B virus HA per mouse and
vaccination) of a human seasonal trivalent vaccine matched to the challenge strain. This
regimen is similar to two-dose regimens recommended for the vaccination of children
(inﬂuenza naive). Animals were then challenged 4 weeks after the last vaccination with
a lethal dose of diverse inﬂuenza B viruses representing the ancestral (39), Victoria-like,
and Yamagata-like (24) lineages.
Challenge with the Victoria-like strain B/Malaysia/2506/04 resulted in transient
weight loss, with a 7.3% mean maximum weight loss on day 7 postchallenge (Fig. 2B),
but full survival in cHA/Bcys-vaccinated animals (Fig. 2C). The cHA/Bala-vaccinated
animals showed slightly greater weight loss, with one animal succumbing to infection
on day 9 postchallenge (Fig. 2B and C). Positive-control animals vaccinated with the
matched standard of care showed weight loss similar to that of cHA/B-vaccinated
animals and were completely protected from mortality, as expected. Both prime-only
animal groups suffered severe weight loss, with no survival in the prime-onlyala group
and 40% survival in the prime-onlycys group. All naive animals succumbed to infection
by day 9 postinfection. Differences in survival between cHA/B-vaccinated groups and
naive animals were signiﬁcant, while no statistical difference could be detected be-
tween cHA/B-vaccinated and SOC groups.
Lethal challenge with the antigenically distinct Yamagata-like B/Florida/04/06 virus
produced similar results. In this case, the percentages of weight loss for cHA/Bcys,
cHA/Bala, and matched SOC groups were very similar (approximately 10% maximum
weight loss in all groups) and transient, with complete protection from mortality (Fig.
2D and E). Naive animals as well as animals in both prime-only groups succumbed to
infection on day 8 and day 9 postchallenge, respectively. Again, differences in survival
between cHA/B-vaccinated groups and naive animals were signiﬁcant, but no statistical
difference was detected between cHA/B-vaccinated and SOC groups.
Since the cHA/Bcys constructs worked slightly better in the B/Malaysia/2506/04
challenge study, we moved this construct design forward to test protection against the
ancestral B/Lee/40 strain (39), which is antigenically distinct from both the Victoria-like
as well as the Yamagata-like lineages. This scenario also offered the opportunity to
compare the efﬁcacy of the cHA/B vaccination regimen with that of the current
standard of care against an antigenically mismatched virus. In this case, two SOC
groups were used, one that received the B/Malaysia/2506/04-containing vaccine (SOC-
Vic) and a second one that received the B/Florida/04/06-containing vaccine (SOC-Yam).
A prime-only group and a naive control group were added as well. The cHA/Bcys
vaccination regimen protected mice completely from morbidity and mortality (Fig. 2F
and G). In contrast, animals in both SOC groups lost approximately 20% of their initial
body weight. While animals in the SOC-Vic group survived infection, 40% of the
SOC-Yam-vaccinated animals died from infection. Furthermore, all naive and prime-
only animals succumbed to infection as well. The difference in survival rates between
the cHA/Bcys group and the naive group was statistically signiﬁcant, while there was no
statistically signiﬁcant difference in mortality between the cHA/Bcys group and the two
SOC groups. However, the difference in weight loss between animals in the cHA/Bcys
group and animals in both SOC groups was signiﬁcant on several days postchallenge.
In summary, cHA/B constructs protect mice from challenge with diverse inﬂuenza B
viruses.
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FIG 2 Vaccination with cHA/B constructs protects mice from lethal challenge with inﬂuenza B viruses. (A) Schematic of the
cHA/B-based vaccination regimen (modeled based on data reported under PDB accession number 4M44). Mice were ﬁrst primed with
plasmid DNA expressing cH5/B, followed by protein vaccinations with cH7/B and cH8/B antigens. The animals were then challenged
with different inﬂuenza B viruses 4 weeks after the last vaccination. (B and C) Weight loss (B) and survival (C) of animals challenged
with B/Malaysia/2506/04 (Victoria lineage). cHA/Bcys indicates animals vaccinated with the cHA/B variants that use cysteines as
demarcation lines, and cHA/Bala indicates animals vaccinated with constructs that use alanines instead (as shown in Fig. 1). Prime-only
(prime-onlycys and prime-onlyala) groups received only the indicated prime but were vaccinated with irrelevant proteins. SOC groups
received two vaccinations with a trivalent inactivated human seasonal vaccine containing an inﬂuenza B virus strain matched to the
challenge virus. A sixth group of mice was naive. The statistical difference between cHA/Bcys-vaccinated and naive mice as well as the
difference between cHA/Bala-vaccinated and naive mice were tested and found to be signiﬁcant (P  0.0035 [**] and P  0.0145 [*],
respectively). (D and E) Weight loss (D) and survival (E) of animals vaccinated as described above and challenged with B/Florida/04/06
virus (Yamagata lineage). The statistical difference between cHA/Bcys-vaccinated and naive mice as well as the difference between
cHA/Bala-vaccinated and naive mice were found to be signiﬁcant (P  0.0019 [**] and P  0.0019 [**], respectively). (F and G) Weight
(Continued on next page)
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The cHA/B vaccine regimen induces broadly reactive antibodies. To determine
if sequential vaccination with cHA/B HAs induces broadly reactive antibodies, we tested
sera from vaccinated mice in an enzyme-linked immunosorbent assay (ELISA). We chose
puriﬁed inﬂuenza B virions as the ELISA substrate. This approach has the advantage of
measuring binding to “real” wild-type virions and avoids problems with reactivity
toward the hexahistidine tag or the trimerization domain of puriﬁed recombinant HA.
These tags/domains are also present in the recombinant cHA/B proteins used as
immunogens and might interfere with the assessment of anti-HA titers. However, this
strategy also has some caveats, including the variability of antigen content in the virus
preparations, which makes it hard to compare results obtained with two different
substrates. In addition, the whole-virus preparations contain HA, neuraminidase (NA),
and internal viral proteins, and animals that received the standard of care (trivalent
inactivated inﬂuenza vaccine [TIV]) might react to all of these components, while
cHA/B-vaccinated mice react to HA only, which also makes a direct comparison difﬁcult.
ELISAs were performed against the ancestral strain B/Lee/40; the Yamagata lineage
strains B/Yamagata/16/88, B/Florida/04/06, and B/Phuket/3073/13; as well as the Vic-
toria lineage strains B/Victoria/2/87, B/Malaysia/2506/04, and B/Brisbane/60/08 (Fig. 3A
to G). In all cases, cHA/Bcys and cHA/Bala induced antibody responses that were
signiﬁcantly greater than responses in the prime-only animals, and antibody induction
was relatively constant for all tested strains. Sera from animals that received TIV were
used as positive controls. Importantly, these sera, as mentioned above, react to HA, NA,
and internal proteins of the ELISA substrate, while sera from cHA/B-vaccinated animals
react only with the HA stalk. We also analyzed the induction of antibodies over the
course of the vaccination regimen and found that the second vaccination induced a
higher-level induction than did the ﬁrst vaccination (Fig. 3H). Overall, the cHA/B-based
vaccination strategy led to the induction of broadly reactive antibodies that covered
inﬂuenza B virus strains from 1940 to 2013.
cHA vaccine-based protection from inﬂuenza B virus challenge is antibody
mediated. While we were assuming that the protection observed in the mouse model
was antibody mediated, we investigated whether antibodies alone could confer pro-
tection. Sets of cHA/Bcys, SOC, and naive mice were terminally bled 4 weeks after the
last vaccination. Serum was harvested and pooled within groups. The serum was then
transferred into naive mice, which were challenged with a lethal dose of B/Malaysia/
2506/04 2 h after transfer. Mice that received cHA/Bcys serum suffered only mild
transient weight loss and were completely protected from mortality (Fig. 4A and B).
Mice that received sera from animals that had been vaccinated with the standard of
care matched to the challenge strain were partially protected from mortality, with 60%
of mice surviving. All animals that received serum from naive mice succumbed to
infection by day 9. We then performed microneutralization assays with B/Malaysia/
2506/04 using the same serum pools that were used in the passive-transfer experiment.
We found that only the SOC serum had measurable neutralizing activity, while the
cHA/Bcys and naive sera did not (Fig. 4C). However, the cHA/Bcys serum had strong
activity in an antibody-dependent cell-mediated cytotoxicity (ADCC) reporter assay
with B/Malaysia/2506/04, while SOC serum did not show such activity (Fig. 4D). Finally,
we determined the effect of cHA/B vaccination on virus replication in the lung. Groups
of animals vaccinated with cHA/Bcys, prime-only animals, animals that received the
standard of care, as well as naive animals were challenged with a lethal dose of
B/Malaysia/2506/04 virus, and their lungs were harvested on day 3 or day 6. Vaccination
with cHA/Bcys reduced lung virus titers approximately 10-fold on day 3 and 135-fold on
day 6 compared to those in naive animals. Animals that received the standard of care
FIG 2 Legend (Continued)
loss (F) and survival (G) after B/Lee/40 challenge of animals vaccinated with cHA/Bcys constructs, prime-only animals, naive animals,
or animals vaccinated twice with a trivalent inactivated human seasonal vaccine containing B/Malaysia/2506/04 (SOC-Vic) or
B/Florida/04/06 (SOC-Yam) antigens. The statistical difference between the cHA/Bcys-vaccinated and naive mice was found to be
signiﬁcant (P  0.0019 [**]). *, P  0.05; **, P  0.01.
Ermler et al. Journal of Virology
June 2017 Volume 91 Issue 12 e00286-17 jvi.asm.org 6
FIG 3 Vaccination with cHA/B constructs induces antibody responses against diverse inﬂuenza B viruses. (A to G)
Quantitative ELISA reactivity reported as endpoint titers for animals vaccinated with the cHA/Bcys and cHA/Bala
(Continued on next page)
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showed only a 2.6-fold reduction on day 3, but virus was not detectable in two out of
three animals on day 6 postchallenge (Fig. 4E). In summary, we show that protection by
cHA/B-based vaccination is antibody mediated, most likely via Fc effector functions.
DISCUSSION
Similar to inﬂuenza A viruses, both inﬂuenza B virus lineages undergo rapid anti-
genic drift, and vaccines have to be updated and readministered on an annual basis.
This is further complicated by the fact that two distinct lineages of inﬂuenza B viruses
are cocirculating in the human population (24). Vaccine strain selection is based on
surveillance/prediction, and selection of a vaccine strain that matches the circulating
pathogenic strains is key to achieving high vaccine efﬁcacy and effectiveness. Histori-
cally, mismatches between vaccine strains and circulating strains have happened
frequently for inﬂuenza B viruses, partially due to the unpredictable dynamics of the
cocirculation of the two lineages (7). While the inclusion of both inﬂuenza B virus
lineages in modern quadrivalent inﬂuenza virus vaccines alleviated this problem, the
issue of antigenic drift remains. Here, a broadly protective vaccination regimen based
on chimeric HAs, which has been successfully developed for inﬂuenza A viruses (28),
was adapted to inﬂuenza B virus. Head domains from exotic avian inﬂuenza A virus HA
subtypes (H5, H7, and H8) were grafted onto inﬂuenza B virus HA stalks. These
constructs were then used in sequential vaccination experiments in mice to refocus the
immune response toward the conserved HA stalk domain. Our experiments show that
vaccination with these constructs can induce cross-reactive antibodies against a wider
range of diverse inﬂuenza B viruses, including isolates from the ancestral, Yamagata-
like, and Victoria-like lineages (Fig. 5). The vaccination regimen afforded robust pro-
tection against challenge with diverse strains. Through serum transfer challenge ex-
periments, we determined that antibodies alone could protect animals from virus
challenge. Interestingly, only negligible neutralizing activity was detected when serum
was tested against one of the challenge strains. However, the serum was highly active
in an ADCC reporter assay that measures Fc-mediated effector functions, an important
mechanism of protection for HA stalk-reactive antibodies (40–46). The nonneutralizing
nature of the antibody response combined with its ADCC activity mirror the charac-
teristics of human monoclonal antibody (MAb) CR9114. This monoclonal antibody
binds broadly to inﬂuenza B virus HAs but is unable to neutralize the virus in vitro (47).
However, it shows strong activity in ADCC reporter assays, and it is highly protective
against challenge with diverse inﬂuenza B virus strains in vivo.
Humans have low titers of antibodies that are reactive against the stalk of the
inﬂuenza B virus HA. A vaccine that induces high titers of these antibodies, either as a
stand-alone vaccine or in combination with inﬂuenza A virus components, would be a
highly valuable prophylactic tool for the control of inﬂuenza.
MATERIALS AND METHODS
Cells, viruses, and recombinant proteins. HEK 293T cells were maintained in Dulbecco’s modiﬁed
Eagle medium (DMEM; Gibco) with 10% fetal bovine serum (FBS; Gibco), 2 mM L-glutamine, and a
penicillin (100 U/ml)-streptomycin (100 g/ml) solution (Pen-Strep; Gibco). Madin-Darby canine kidney
(MDCK) cells were grown in DMEM (Gibco) supplemented with 10% FBS and penicillin-streptomycin. Sf9
cells for baculovirus rescue and propagation were grown in Trichoplusia ni medium-formulation Hink
(TNM-FH) insect cell medium (Gemini Bioproducts) supplemented with 10% FBS and penicillin-
streptomycin. BTI-TN-5B1-4 (High Five) cells for protein expression were grown in serum-free SFX
medium (HyClone) supplemented with penicillin-streptomycin. Virus preparations for inﬂuenza B virus
FIG 3 Legend (Continued)
constructs and their respective prime-only groups (prime-onlycys and prime-onlyala) as well as for naive animals. Sera
from animals that received inactivated inﬂuenza B virus vaccines were used as positive controls. A panel of puriﬁed
inﬂuenza B viruses representing the ancestral, Victoria (Vic), and Yamagata (Yam) lineages was used as the ELISA
substrate. Strains are indicated. Importantly, the reactivity of serum from cHA/B-vaccinated animals is directed against
HA only, while positive-control serum is the sum of the reactivity to HA, NA, and conserved internal viral proteins. The
geometric mean is indicated for each sample set (n  10 for all groups except the positive-control groups [n  5]).
(H) Proﬁle of reactivity against one selected substrate (B/Florida/04/06) over the course of the vaccination experiment.
Statistical signiﬁcance is indicated where tested (n.s., not signiﬁcant [P  0.05]; *, P  0.05; **, P  0.01).
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strains B/Lee/40, B/Yamagata/16/1988, B/Victoria/2/1987, B/Florida/4/2006, B/Malaysia/2506/04, B/Bris-
bane/60/2008, and B/Phuket/3073/2013 were generated as follows. Viruses were grown in 10-day-old
embryonated chicken eggs (Charles River) for 72 h at 33°C. Eggs were then cooled down to 4°C
overnight, and allantoic ﬂuid was harvested and cleared by low-speed centrifugation at 2,000  g for 10
min at 4°C. Viruses were then pelleted through a 30% sucrose cushion (buffered in NTE buffer [100 mM
NaCl, 10 mM Tris-HCl, 1 mM EDTA {pH 7.4}]) by centrifugation in a Beckman L7-65 ultracentrifuge at
25,000 rpm for 2 h at 4°C using a Beckman SW28 rotor. Pellets were collected in phosphate-buffered
FIG 4 Protection induced by chimeric HA/B HA vaccination is mediated by antibodies, likely via Fc-mediated effector functions. (A and
B) Weight loss (A) and survival (B) of mice that received passive transfer of serum from cHA/Bcys, SOC (animals received two vaccinations
with a human seasonal inactivated vaccine containing the B/Malaysia/2506/04 inﬂuenza B virus component), or naive animals and were
subsequently challenged with B/Malaysia/2506/04 (Victoria lineage). Differences in survival between the cHA/Bcys and naive groups were
statistically signiﬁcant (P  0.0023 [**]). (C) Neutralizing activity of sera from cHA/Bcys, SOC, and naive animals tested in a microneutral-
ization assay with B/Malaysia/2506/04 virus. (D) Activity of the same sera in an ADCC reporter assay. (E) Day 3 and day 6 lung virus titers
in animals directly vaccinated with cHA/Bcys and in animals in the prime-only (prime-onlycys), SOC, and naive groups after challenge with
B/Malaysia/2506/04. Statistical signiﬁcance is indicated where tested (**, P  0.01).
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saline (PBS) (pH 7.4), and the protein content was quantiﬁed by using the Bradford reagent. Challenge
viruses were grown in eggs as described above, and titers of the virus stocks were determined on
monolayers of MDCK cells.
Design of chimeric HA vaccine constructs. Chimeric inﬂuenza virus A/B HA (cHA/B) constructs
consist of an inﬂuenza A virus HA head atop an inﬂuenza B virus HA stalk. Constructs were designed to
have HA stalks derived from B/Yamagata/16/88 and heads from either H5 (from a low-pathogenic version
of A/Vietnam/1203/2004 [48], named cH5/B), H7 (A/mallard/Alberta/24/2001, named cH7/B), or H8
(A/mallard/Sweden/24/2002, named cH8/B) inﬂuenza A virus HA. Two designs were assembled for each
inﬂuenza A virus HA head that was used. The ﬁrst design includes a pair of cysteines at the head/stalk
interface similar to those observed in inﬂuenza A virus HAs (at positions 52 and 277 [H3 numbering]).
These residues had previously been used as a demarcation line for the head/stalk interface generating
inﬂuenza A virus chimeric HAs (29, 30). These constructs are referred to as cH5/Bcys, cH7/Bcys, and
cH8/Bcys. The second design replaces the pair of cysteines that would naturally encompass the inﬂuenza
A virus HA head with a pair of alanines that are found in inﬂuenza B virus HAs at approximately the same
location. These constructs are referred to as cH5/Bala, cH7/Bala, and cH8/Bala. The alanines (positions 57
and 306 [B/Yamagata/16/88 numbering, starting at methionine]) used as a demarcation line were
determined by performing sequence alignment between inﬂuenza A and inﬂuenza B virus HA protein
sequences with the BioEdit Sequence Alignment Editor (1997 to 2013; Tom Hall) and using crystal
structure visualization programs such as the Molecular Operating Environment (MOE; Chemical Com-
puting Group) and PyMOL (Schrödinger, Inc.). The constructs were then created via overlapping
extension PCRs or were synthesized (Thermo Fisher Scientiﬁc/Invitrogen) and subcloned into pDZ
plasmids for transfection of mammalian cells or into a pHA baculovirus shuttle vector for protein
expression and puriﬁcation (primer sequences are available upon request). As initial attempts to rescue
the virus using this cHA/B HA constructs were made by using reverse genetic approaches, all clones were
constructed with packaging signals derived from A/Puerto Rico/8/34 (PR8) virus and included the PR8
noncoding regions, signal peptide, transmembrane domain, and cytoplasmic tail domain. For the
expression of recombinant proteins, the HA ectodomain open reading frames were cloned into the pHA
baculovirus shuttle vector in frame with a C-terminal T4 trimerization domain and a hexahistidine tag, as
FIG 5 Phylogenetic tree representing inﬂuenza B virus HA diversity. Strains used as challenge strains
(B/Malaysia/2506/04 and B/Florida/04/06) or as ELISA substrate in this study are indicated. The bar
indicates a 1% change in the amino acid sequence.
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described previously (49, 50). Recombinant bacmids and, subsequently, baculoviruses were generated,
and proteins were expressed in BTI-TN-5B1-4 cells and puriﬁed from the culture supernatant according
to an established protocol (49). The protein concentration was measured by using the Bradford reagent
and a standard curve.
Surface staining. Twenty-four-well plates were coated with poly-L-lysine (Sigma-Aldrich), and 1.5 
104 HEK 293T cells were seeded per well. The next day, cells were transfected with 500 ng of each
plasmid in optimized minimal essential medium (MEM) (Opti-MEM; Gibco) with Lipofectamine 2000
(Thermo Fisher Scientiﬁc) at a 1:2 ratio. Twenty-four hours later, medium was removed, and cells were
ﬁxed with 4% paraformaldehyde in PBS for at least 1 h at room temperature (RT). Cells were washed with
PBS and blocked with 5% BSA in PBS. Primary anti-B/Yamagata/16/88 murine polyclonal serum was
diluted 1:500 in 1% BSA–PBS and incubated on cells for at least 2 h at RT. Cells were washed with PBS
and incubated with an anti-mouse Alexa-488 antibody (Life Technologies) diluted 1:1,000 in 1% BSA–PBS
for at least 1 h at RT. Fluorescence was visualized and captured by using an Olympus 1X-70 microscope
within the Microscopy Core at the Icahn School of Medicine at Mount Sinai.
Animal experiments. Six- to eight-week-old female BALB/c mice were used for all animal experi-
ments (Jackson Laboratories). Experiments were performed in accordance with protocols approved by
the Icahn School of Medicine at Mount Sinai Institutional Animal Care and Use Committee (IACUC). For
initial experiments, animals were divided into six groups (n  5) per challenge virus. The six groups
included a group that was DNA vaccinated with cH5/Bcys and then vaccinated with cH7/Bcys and cH8/Bcys
proteins (cHA/Bcys), a group that was DNA vaccinated with cH5/Bcys and then vaccinated twice with BSA
as an irrelevant protein (prime-onlycys), a group that was DNA vaccinated with cH5/Bala and then
vaccinated with cH7/Bala and cH8/Bala proteins (cHA/Bala), a group that was DNA vaccinated with cH5/Bala
and then vaccinated twice with BSA (prime-onlyala), a group that received a trivalent inactivated vaccine
that matched the challenge strain (SOC), and a naive group of mice. DNA vaccines were delivered via
intramuscular electroporation in the left calf muscle via a TriGrid electroporation device (Ichor Medical
Systems) at a dose of 80 g DNA per mouse (40 l at 2 mg/ml in double-distilled water [ddH2O]). DNA
priming was included in the experimental design to make the results comparable to data from previous
studies with group 1 and group 2 cHA vaccines (31, 36). Protein vaccines (cHA/B HAs) or BSA was
administered both i.n. and i.m. at the same time at a dose of 10 g per mouse (5 g i.n. and 5 g i.m.;
50 l per vaccination site), adjuvanted with 10 g of poly(I·C) (InvivoGen) per mouse per site. The SOC
was given unadjuvanted at a dose of 1 g of inﬂuenza B virus HA per mouse. The Fluzone vaccine (2006
to 2007; Sanoﬁ Pasteur) (includes the B/Malaysia/2506/04 strain) was used for B/Malaysia/2506/04
challenges, and the Flulaval vaccine (2008 to 2009; GlaxoSmithKline) (includes the B/Florida/04/06 strain)
was used for B/Florida/04/06 challenge experiments. Vaccinations were given at 3-week intervals. Four
weeks after the last vaccination, animals were anesthetized with a ketamine-xylazine cocktail (0.15 mg/kg
of body weight of ketamine and 0.03 mg/kg of xylazine per mouse) and then challenged intranasally with
5 murine 50% lethal doses (mLD50) of mouse-adapted B/Malaysia/2506/04 (1 LD50 equals 2.5  103 PFU),
mouse-adapted B/Florida/04/06 (1 LD50 equals 3.2  103 PFU), or B/Lee/40 (1 LD50 equals 2.2  105 PFU)
virus in a volume of 50 l. Mouse adaptation was performed prior to the U.S. government “gain-of-
function” moratorium in 2014. Animals were monitored for survival and weight loss for 14 days
postchallenge and were scored dead and humanely euthanized if they lost more than 25% of their initial
body weight. Additional experiments to assess virus replication in the lungs and the protective effect of
transferred serum were performed. To determine lung virus titers, animals of selected groups (vaccinated
as described above) were challenged as described above with 5 mLD50 of B/Malaysia/2506/04 virus.
Lungs from groups of animals were harvested on days 3 and 6 postchallenge (n  3 per group and time
point). Lungs were then homogenized by using a BeadBlaster homogenizer (Benchmark), and lung virus
titers were determined by a plaque assay on conﬂuent layers of MDCK cells as described previously (51).
For passive-transfer experiments, groups of mice (n 5) were terminally bled, and serum was harvested,
pooled within the groups, and transferred (200 l per mouse) into groups of naive mice (n  5) via
intraperitoneal (i.p.) injection. Two hours after transfer, the mice were anesthetized and challenged with
5 mLD50 of B/Malaysia/2506/04 virus as described above.
ELISAs. A quantitative ELISA that uses the reciprocal endpoint titer as a readout was used in this
study to evaluate the antibody response to inﬂuenza B viruses. ELISA plates (Immulon 4HBX; Thermo
Scientiﬁc) were coated with 5 g/ml of the whole-virus preparation per well (50 l per well) in coating
buffer (carbonate-bicarbonate buffer [pH 9.4]) overnight at 4°C. The next day, plates were washed three
times with PBS containing 0.1% Tween 20 (PBS-T), blocking solution (3% goat serum, 0.5% nonfat dried
milk powder, 96.5% PBS-T) was added to each well, and the plates were incubated for 1 h at RT. Serum
samples were serially diluted in blocking solution and added to the plate, followed by a 2-h incubation
at RT. ELISA plates were washed three times with PBS-T, and anti-mouse IgG-horseradish peroxidase
(HRP)-conjugated antibody (GE Healthcare) was added at a dilution of 1:3,000. Plates were then
incubated for 1 h at RT and washed three times with PBS-T. The O-phenylenediamine dihydrochloride
(OPD) substrate (SigmaFast OPD; Sigma) was added, and after 10 min of incubation, the reaction was
stopped by adding 50 l of 3 M HCl to the mixture. The optical density (OD) was measured at 490 nm
on a Synergy 4 plate reader (BioTek). A cutoff value of the average of the OD values of blank wells plus
3 standard deviations was established for each plate and used for calculating the reciprocal endpoint
titer, which was the readout for this assay. The limit of detection of the assay was a titer of 1:100; samples
that did not reach this titer were assigned a value of 1:50 for calculation and graphing purposes.
Neutralization assay. Pooled serum samples were diluted 1:4 and treated with receptor-destroying
enzyme (RDE; Denko Seiken) for 18 h at 37°C. RDE treatment was inactivated with 2.5% sodium citrate,
resulting in a 1:10 dilution of serum from the starting concentration. RDE-treated serum was then added
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to wells of a 96-well plate and serially diluted 1:2 in MEM with 1% tosyl phenylalanyl chloromethyl ketone
(TPCK) trypsin and penicillin-streptomycin. A total of 1,000 PFU/well of B/Malaysia/2506/04 were added
to the wells and left to incubate for 1 h at room temperature. MDCK cells (plated at 500,000 cells per well
for 24 h) were then washed one time with 1 PBS and incubated in the virus-serum mixture for 1 h at
37°C. The cells were washed again with 1 PBS and then incubated with serum dilutions for 72 h at 33°C.
The cell supernatant was then mixed 1:1 with 0.5% chicken red blood cells and incubated for 40 min at
4°C. Hemagglutination was used as a determination of virus present in the samples. The last serum
dilution without hemagglutination was deﬁned as the minimal neutralizing titer.
ADCC reporter assay. The Promega ADCC Reporter Bioassay kit (catalog number G7010) was used
for this experiment. MDCK cells plated onto an opaque 96-well plate (at 50,000 cells per well) were
infected 24 h later with B/Malaysia/2506/04 at a multiplicity of infection (MOI) of 5 for a single cycle (no
TPCK-treated trypsin was added) overnight. Sera were diluted 1:3 (from a starting dilution of 1:150) in
Roswell Park Memorial Institute (RPMI) medium and added to the virus-infected cells, followed by the
addition of ADCC mouse effector cells (Promega), and plates were incubated for 6 h at 37°C. Lumines-
cence was read by using a Synergy 4 plate reader and Gen5 2.09 software, and induction over the
baseline was calculated and reported.
Statistical analysis and phylogenetic analysis. ELISA endpoint titers were compared by using
Student’s t test. Differences in survival were tested for signiﬁcance by using the Mantel-Cox log rank test.
Differences in weight loss were analyzed per day by using one-way analysis of variance (ANOVA) for
multiple comparisons. Statistical analysis was performed by using Prism (GraphPad). For phylogenetic
analysis, sequences were downloaded from the Global Initiative on Sharing All Inﬂuenza Data (GISAID)
database with ﬁlters to remove duplicates and laboratory-originating strains. The sequences were then
aligned by using MUSCLE, and the alignment was edited by using MEGA 6.06 software. Aligned
sequences were then translated and randomly subsampled at 30 sequences per year after the year 2001.
Subsampling was performed to avoid bias toward recent isolates. Only a few sequences are available per
year before 2001, and therefore, subsampling was not applicable for earlier years. A phylogenetic tree
was assembled by using the Clustal Omega Web server with a neighbor-joining clustering method using
442 sequences. The tree was visualized by using FigTree software, and annotations were made in Adobe
Illustrator.
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